Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Non-Current Assets of $623.1 million for Q1 2026, down 14.52% on a YoY basis from $728.9 million in Q1 2025, and down 3.82% quarter-over-quarter from $647.9 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Non-Current Assets for 7 years, with the latest figure at $623.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 14.52% year-over-year to $623.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (down 15.86% YoY), and the FY2025 full-year result was $647.9 million, down 16.37% from the prior year.
- Non-Current Assets for Q1 2026 stood at $623.1 million, down from $647.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.1 billion in Q1 2023, with the low at $351.9 million in Q1 2022.
- Historically, Non-Current Assets has averaged $732.7 million across 5 years, with a median of $708.0 million in 2025.
- The largest YoY upside for Non-Current Assets was 213.05% in 2022 against a maximum downside of 79.6% in 2022.
- Ginkgo Bioworks Holdings' Non-Current Assets stood at $1.1 billion in 2022, then plunged by 39.08% to $663.6 million in 2023, then grew by 16.74% to $774.7 million in 2024, then slipped by 16.37% to $647.9 million in 2025, then slipped by 3.82% to $623.1 million in 2026.
- The last three Non-Current Assets figures came in at $623.1 million (Q1 2026), $647.9 million (Q4 2025), and $683.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | 623.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623.12 Mn |
| Dec 31, 2025 | 647.86 Mn |
| Sep 30, 2025 | 683.08 Mn |
| Jun 30, 2025 | 707.98 Mn |
| Mar 31, 2025 | 728.93 Mn |
| Dec 31, 2024 | 774.71 Mn |
| Sep 30, 2024 | 818.40 Mn |
| Jun 30, 2024 | 841.89 Mn |
| Mar 31, 2024 | 678.74 Mn |
| Dec 31, 2023 | 663.59 Mn |
| Sep 30, 2023 | 884.55 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.09 Bn |
| Dec 31, 2022 | 1.09 Bn |
| Sep 30, 2022 | 408.69 Mn |
| Jun 30, 2022 | 395.37 Mn |
| Mar 31, 2022 | 351.89 Mn |
| Dec 31, 2021 | 347.95 Mn |
| Sep 30, 2021 | 340.02 Mn |
| Jun 30, 2021 | 1.73 Bn |